1mg Business Model Explained: Operations, Revenue Streams & Growth Strategy

How does 1mg make money in one sentence?

1mg earns money through margins on medicine sales, commissions on diagnostic lab tests, doctor consultation fees, Care Plan subscriptions, advertising from pharma and FMCG brands, and B2B corporate health partnerships, all built on top of a content and SEO engine that drives most of its traffic without paid ads.

That last detail is the part most "1mg business model" articles skip entirely, and it's arguably the most important one if you're building a healthtech platform yourself.

From a Medicine Information Website to India's Biggest E-Pharmacy

1mg started in 2013 as HealthkartPlus, a simple website that let people search for information about medicines, what they treat, their side effects, and their generic alternatives. It was not selling anything yet. It was just answering questions people had typed into Google and could not find good answers to.

Founders Prashant Tandon, Gaurav Agarwal, and Vikas Chauhan rebranded it as 1mg in April 2015, once that informational traffic gave them the confidence (and the data) to know exactly what their users actually wanted: not just information, but the ability to order the medicine they'd just searched for, immediately, without driving to a pharmacy.

Tata Digital acquired a majority stake in 2021 for an estimated $230 million, and the platform became Tata 1mg. By March 2025, Tata 1mg had grown into India's dominant online pharmacy with ₹2,360 crore in revenue, up 22% year on year, and 31% market share, ahead of both PharmEasy and Apollo 24/7. It now serves more than 40 million users and generates 500 million monthly page views.

In January 2026, Tata 1mg announced a major expansion into nearly 500 offline stores nationwide, a notable pivot for a company that built its entire reputation as a digital-first platform. That single move tells you a lot about where healthtech delivery is heading in India, and it's worth understanding in detail if you're thinking about building something similar.

How 1mg Actually Works

The user journey is simple by design. Open the app, search for a medicine by name, brand, or condition, or upload a doctor's prescription. The platform shows available options including generic alternatives, often at a lower price than the branded version the doctor prescribed.

Add to cart, pay through the app, and 1mg routes the order to its nearest partner pharmacy or its own fulfilment centre. A delivery partner picks it up and delivers it, typically within a few hours in metro cities and within a day or two in smaller towns.

Beyond medicine, the same app lets you book a diagnostic lab test with home sample collection, book a video consultation with a doctor, and shop for health supplements, devices, and Ayurvedic or homeopathic products. Three separate verticals (Pharmacy, Labs, Doctors) feeding into one app and one customer relationship.

This is the structural insight worth sitting with 1mg doesn't sell one thing. It sells access to an entire healthcare journey, and every part of that journey reinforces the others. A lab test result naturally leads to a doctor consultation. A doctor consultation naturally leads to a prescription. A prescription naturally leads to a medicine order. Each step funds and feeds the next.

The Five Revenue Streams Behind 1mg

1. Medicine Sales (The Core Engine)

1mg earns a margin of 10 to 25% on every medicine order, whether prescription or over-the-counter, after accounting for logistics and vendor payouts. This is still the platform's largest single revenue driver. Private-label health products, where 1mg sells its own branded supplements and OTC items rather than third-party brands, can lift margins by up to 30% compared to a pure marketplace model, which is exactly why Tata 1mg has been steadily expanding its own product lines.

2. Diagnostic Lab Commissions

Through partnerships with over 2,500 NABL-accredited labs, 1mg lets users book lab tests and health packages with home sample collection. The platform earns a commission of 20 to 30% per test booked, and the more premium the diagnostic package, the higher the revenue share. Chronic patients, the people who need recurring blood work, thyroid panels, or diabetes monitoring, contribute up to 60 to 70% of repeat orders on platforms like this, which makes diagnostics one of the most reliable recurring revenue lines in the entire business.

3. Doctor Consultation Fees

Teleconsultation isn't just a convenience feature. It's a direct revenue stream and the connective tissue that ties the whole platform together. A consultation generates a fee, but more importantly it generates a prescription, which routes straight back into medicine sales. This closed loop, consult, prescribe, fulfil, all inside one app, is what makes 1mg materially stickier than a platform that only sells medicine.

4. Care Plan Subscriptions

1mg Care Plan is a monthly or annual membership giving subscribers unlimited free doctor consultations, free home sample collection for lab tests, extra discounts on medicine and tests, and priority support. This is the platform's recurring revenue layer, and it works the same way subscriptions work everywhere else in on-demand delivery a customer who has already paid orders more often to justify the cost, lowering churn and raising lifetime value at the same time. This same subscription logic is what makes Rapido's driver subscription model work so well in ride-hailing a paid-up user or driver behaves differently, and more loyally, than a pay-per-use one.

5. Advertising, Sponsored Listings, and Corporate Partnerships

1mg sells ad space and featured listings to pharma brands and FMCG health companies who want visibility in front of 40 million active users. This is high-margin revenue with close to zero marginal cost once the platform exists. On top of that, Tata 1mg has been building a serious B2B layer: a December 2025 partnership with OneBanc specifically targets India's ₹30,000 crore corporate health benefits burden, giving 1mg a direct line into employer-funded healthcare spending rather than relying purely on individual consumer transactions.

The Growth Strategy: What 1mg Did Differently

Most e-pharmacy and healthtech apps in India spent heavily on Google and Meta ads to acquire users. 1mg took a different route, and it's the single most replicable lesson in this entire case study.

It built a medical content library covering more than 10,000 health topics, every symptom, every medicine, every condition, written and reviewed by actual doctors and medical writers, and optimised relentlessly for the exact questions people type into search engines when they're worried about their health. Someone searching "metformin side effects" or "is paracetamol safe during pregnancy" lands on a 1mg page with a real, useful, medically reviewed answer, and a clear path to order the medicine or book a related test right there.

The result by FY25 ₹2,360 crore in revenue, up 22%, while advertising spend actually fell 37% year on year. Most growth-stage startups can't say that. Paid acquisition stops the moment you stop paying for it. A piece of medical content published in 2016 is by 1mg's own numbers, still driving traffic and conversions nearly a decade later.

Tata kept this strategy after acquiring the company in 2021 and expanded it rather than replacing it with paid growth, which tells you Tata's own data confirmed it was the right call.

Beyond content, three other growth moves stand out for 2025 and 2026. The Unicommerce partnership in 2025 focused on eCommerce operational efficiency at scale. The ClickPost partnership in November 2025 brought AI-powered logistics automation specifically to medicine delivery, where speed and accuracy genuinely matter more than in general retail. And the January 2026 expansion into nearly 500 offline stores signals a hybrid online-offline model, the same direction grocery and quick-commerce platforms have been moving in, where physical locations support faster fulfilment and build trust with customers who still want to walk into a pharmacy for certain purchases.

1mg vs. PharmEasy vs. Apollo 24/7

1mg holds 31% market share, ahead of both major competitors. PharmEasy, once the dominant player, has lost ground partly due to financial restructuring and funding pressure in recent years. Apollo 24/7 has the advantage of being directly tied to Apollo's hospital and pharmacy network, giving it strong offline trust, but it hasn't matched 1mg's organic content and search dominance.

The honest read 1mg's edge isn't its product catalogue, every major e-pharmacy sells broadly the same medicines. Its edge is owning the moment someone first searches for a health concern, long before they've decided which app to order from. By the time a customer is ready to buy, 1mg has often already answered their question for free and earned the trust that makes the purchase decision easy.

The same logic about cross-vertical platforms feeding each other shows up clearly in Zomato's multi-unit business model, where food delivery, quick commerce, B2B supply, and events all reinforce one customer relationship rather than four separate businesses competing for the same user's attention.

What This Means If You're Building a Healthtech Delivery App

Lead with content, not ads, if you can afford to be patient. 1mg proved that medically credible, search-optimised content compounds in a way paid acquisition never will. If you're entering healthtech, invest early in genuinely useful health content rather than burning your seed round entirely on Meta ads.

Build the closed loop from day one. Medicine sales alone are a thin-margin, commoditised business. The real value is in connecting medicine, diagnostics, and consultations into one customer journey where each part feeds the next. A platform that only delivers medicine is competing purely on price and speed. A platform that connects consultation to prescription to fulfilment is competing on trust and convenience, a much harder position for competitors to attack.

Subscriptions matter more in healthcare than almost any other vertical. Chronic condition management means recurring need. A Care Plan-style subscription that bundles consultations, lab discounts, and medicine discounts captures that recurring need far more effectively than one-off transactional pricing.

B2B corporate health is an underused revenue layer. 1mg's OneBanc partnership targeting India's corporate health spending shows where a meaningful chunk of future healthtech revenue sits. If you're building in this space, talk to HR and benefits teams at mid-size companies early, not as an afterthought once your consumer app has scaled.

If you're deciding how to structure the technology behind any kind of delivery platform, whether medicine, groceries, or general retail, our delivery app development guide covers the four-app architecture (customer, partner pharmacy or merchant, delivery, admin) that 1mg-style platforms are built on, and the same logic that powers AI-driven demand forecasting and substitution in grocery apps applies just as directly to predicting medicine stock and avoiding out-of-stock situations on critical prescriptions.

For the decision between building this kind of platform from scratch versus launching with a proven white-label foundation, our clone app vs custom app development guide walks through exactly how to make that call based on your budget, timeline, and how quickly you need to validate demand.

And because the underlying delivery mechanics, real-time tracking, dispatch, last-mile routing, are the same whether you're delivering pizza or paracetamol, the operational lessons in our last-mile delivery AI guide and our breakdown of Blinkit's inventory-led dark store model are directly relevant if you're considering a hybrid online-offline pharmacy model the way 1mg is now building with its 500 new physical stores.

Challenges 1mg Still Faces

Revenue concentration risk. A large share of revenue still comes from commission on medicine sales. If competition intensifies or regulation tightens around online drug sales, that core revenue line is exposed.

Regulatory pressure on e-pharmacy. India's government has tightened rules around online prescription verification and drug sales repeatedly over the past several years. Any platform operating in this space needs continuous compliance investment, not a one-time setup.

Margin pressure from low-cost competitors. Generic-focused discounters and regional players compete aggressively on price for commodity medicines, which puts pressure on 1mg to keep differentiating through diagnostics, subscriptions, and content rather than price alone. This is the same competitive dynamic that forced Swiggy and Zomato into a margin war in quick commerce, where differentiation through speed and service mattered more than price alone.

The offline expansion is a genuinely new operational challenge. Running 500 physical stores is a different business than running a content and delivery platform. Real estate, staffing, and inventory management at physical locations require capabilities Tata 1mg has not needed to build at this scale before.

Ready to Build Your Own Healthtech Delivery Platform?

1mg built India's largest online pharmacy not by being the cheapest or the fastest, but by becoming the place people trust the moment they have a health question, long before they're ready to buy anything. That trust, built through content, reinforced through a connected medicine-diagnostics-consultation loop, and monetised through a genuinely diversified set of revenue streams, is the real lesson here.

You don't need Tata's balance sheet to apply the same principles at a smaller scale in your own market or niche.

Brineweb's delivery app development platform gives you a production-ready foundation for medicine, healthcare, and any prescription or appointment-based delivery service. Customer app, pharmacy or merchant dashboard, delivery partner app, real-time order tracking, and an admin console, all configurable for your market.

Get a free quote from Brineweb and find out exactly what it costs to launch your own healthtech delivery platform.